News


All series


All News

Despite recommendations from the United States Preventative Services Task Force, 1.9% of the 7.6 million current and former heavy smokers underwent cancer screening in 2016, suggesting screening is still inadequate. These results were presented ahead of the 2018 ASCO Annual Meeting being held in Chicago, Illinois on June 1-5, 2018.

According to findings&nbsp;released ahead of the 2018 ASCO Annual Meeting, the use of next-generation sequencing (NGS) for patients with&nbsp;metastatic non&ndash;small cell lung cancer (NSCLC) can save&nbsp;Center for Medicare and Medicaid Services (CMS) payers $1.4 million to $2.1 million. The findings additionally showed that NGS saved commercial insurance providers more than $250,000.<br /> &nbsp;

Epoetin alfa-epbx (Retacrit) has been approved by the FDA&nbsp;as a biosimilar to epoetin alfa (Epogen/Procrit) for the&nbsp;treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.&nbsp;

The adjuvant treatment landscape of gastrointestinal cancers has recently undergone a transformation, with significant findings from several clinical trials. These studies, in gastric, biliary, pancreatic, and colon cancer looked particularly at the use of treatment in the adjuvant setting after surgical resection and have ultimately changed the standards of care for these patients.

Ivan Borrello, MD, recently shared the treatment considerations and decisions he makes when treating patients with multiple myeloma. Borrello, an associate professor of oncology, Johns Hopkins University School of Medicine, and director of cell therapy, Sydney Kimmel Comprehensive Cancer Center, in Baltimore, Maryland, explained his treatment decisions based on a case scenario during a <em>Targeted Oncology</em> live case-based peer perspective presentation.

Updated results from the phase II LuPSMA study published in<em> The Lancet Oncology </em>showed radionuclide treatment with&nbsp;Lutetium-177 [<sup>177</sup>Lu]-PSMA-617 nearly doubled median PSA progression-free survival in men with progressive metastatic castrate-resistant prostate cancer compared with previous results with another radiopharmaceutical, radium-223.

On Friday, President Donald Trump proposed a &ldquo;blueprint&rdquo; of widespread changes designed to reduce prescription drug costs, drawing a lot of attention from oncology groups and patient advocates across the nation. The proposal, a 44-page plan titled, <em>American Patients First,</em>&nbsp;promises to make generic drugs and biosimilars more accessible. Incentives keeping drug prices high will also be removed.

Ben Levy, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic non&ndash;small cell lung cancer. Levy, clinical director of Medical Oncology, John Hopkins Sydney Kimmel Center, Washington, DC, explained his treatment decisions based on a case scenario during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.

According to additional analyses from the phase III RESORCE trial published in the<em> Journal of Hepatology,&nbsp;s</em>econd-line regorafenib continued to show antitumor activity regardless of prior dose or time to progression on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma.

The American Society of Clinical Oncology (ASCO) and the Conquer Cancer Foundation of ASCO (CCF) have announced the winners of ASCO&rsquo;s Special Awards and&nbsp;Conquer Cancer&rsquo;s Women Who Conquer Cancer Mentorship Awards to honor the many contributions of&nbsp;researchers, patient advocates, and global oncology leaders around the globe.

Based on findings from the phase III IMpower150 trial, a supplemental biologics license application for atezolizumab has been granted a priority review by the FDA&nbsp;for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non&ndash;small cell lung cancer.